LT3110438T - Uspa2 baltymo konstruktai ir jų panaudojimo būdai - Google Patents

Uspa2 baltymo konstruktai ir jų panaudojimo būdai

Info

Publication number
LT3110438T
LT3110438T LTEP15708341.1T LT15708341T LT3110438T LT 3110438 T LT3110438 T LT 3110438T LT 15708341 T LT15708341 T LT 15708341T LT 3110438 T LT3110438 T LT 3110438T
Authority
LT
Lithuania
Prior art keywords
protein constructs
uspa2 protein
uspa2
constructs
protein
Prior art date
Application number
LTEP15708341.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Normand Blais
Cindy Castado
Patrick Chomez
Marianne Dewerchin
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of LT3110438T publication Critical patent/LT3110438T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045Moraxella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1218Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Acinetobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP15708341.1T 2014-02-24 2015-02-20 Uspa2 baltymo konstruktai ir jų panaudojimo būdai LT3110438T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US201461946937P 2014-03-03 2014-03-03
US201461946932P 2014-03-03 2014-03-03
PCT/IB2015/051308 WO2015125118A1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof

Publications (1)

Publication Number Publication Date
LT3110438T true LT3110438T (lt) 2019-04-10

Family

ID=52629643

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP15708341.1T LT3110438T (lt) 2014-02-24 2015-02-20 Uspa2 baltymo konstruktai ir jų panaudojimo būdai
LTEP18211544.4T LT3498292T (lt) 2014-02-24 2015-02-20 Uspa2 baltymo konstruktai ir jų panaudojimas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP18211544.4T LT3498292T (lt) 2014-02-24 2015-02-20 Uspa2 baltymo konstruktai ir jų panaudojimas

Country Status (28)

Country Link
US (3) US10040832B2 (enExample)
EP (2) EP3498292B1 (enExample)
JP (1) JP6585085B2 (enExample)
KR (1) KR102515835B1 (enExample)
CN (2) CN106061995A (enExample)
AU (1) AU2015220369B2 (enExample)
BE (1) BE1022345A9 (enExample)
BR (1) BR112016019525B1 (enExample)
CA (1) CA2939862C (enExample)
CY (2) CY1121535T1 (enExample)
DK (2) DK3110438T3 (enExample)
EA (1) EA034352B1 (enExample)
ES (2) ES2899300T3 (enExample)
HR (2) HRP20211926T1 (enExample)
HU (2) HUE042054T2 (enExample)
IL (1) IL246994B (enExample)
LT (2) LT3110438T (enExample)
ME (1) ME03335B (enExample)
MX (1) MX376079B (enExample)
PL (2) PL3110438T3 (enExample)
PT (2) PT3498292T (enExample)
RS (2) RS62592B1 (enExample)
SG (1) SG11201606272PA (enExample)
SI (2) SI3110438T1 (enExample)
SM (2) SMT202100728T1 (enExample)
TW (1) TW201620927A (enExample)
UY (1) UY36006A (enExample)
WO (1) WO2015125118A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN110662557A (zh) * 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
JP2020530478A (ja) * 2017-08-14 2020-10-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫応答を強化する方法
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020039033A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
US20230066762A1 (en) 2019-08-05 2023-03-02 Glaxosmithkline Biologicals Sa Immunogenic composition
AU2020325569B2 (en) 2019-08-05 2024-01-18 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein D polypeptide
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0948625B1 (en) * 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US6942802B2 (en) * 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
MXPA04000653A (es) * 2001-07-27 2004-11-22 Chiron Srl Adhesinas de meningococcus nada, app y orf 40.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US8092811B2 (en) * 2005-08-10 2012-01-10 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
ZA200800891B (en) * 2005-08-10 2009-06-24 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
NO346497B1 (no) * 2006-01-17 2022-09-05 Arne Forsgren Overflateeksponert haemophilus influenzae protein (protein E, pE)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
CN103687613A (zh) * 2011-05-11 2014-03-26 里斯贝克保健瑞典股份公司 蛋白f-具有层粘连蛋白和玻连蛋白结合性能的新的流感嗜血杆菌粘附素
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途

Also Published As

Publication number Publication date
US20200325184A1 (en) 2020-10-15
CA2939862C (en) 2022-12-06
TW201620927A (zh) 2016-06-16
US10040832B2 (en) 2018-08-07
EA034352B1 (ru) 2020-01-30
US20180354996A1 (en) 2018-12-13
CN111499701A (zh) 2020-08-07
BE1022345B1 (fr) 2016-03-25
IL246994A0 (en) 2016-09-29
EA201691611A1 (ru) 2016-12-30
CN106061995A (zh) 2016-10-26
US10745449B2 (en) 2020-08-18
HUE057505T2 (hu) 2022-05-28
EP3498292B1 (en) 2021-10-20
CY1124979T1 (el) 2022-11-25
BE1022345A9 (fr) 2016-11-16
AU2015220369A1 (en) 2016-09-15
BR112016019525A2 (pt) 2017-10-24
UY36006A (es) 2015-09-30
DK3110438T3 (en) 2019-03-25
PL3498292T3 (pl) 2022-02-14
RS58451B1 (sr) 2019-04-30
LT3498292T (lt) 2021-11-25
HRP20211926T1 (hr) 2022-03-18
RS62592B1 (sr) 2021-12-31
US10947280B2 (en) 2021-03-16
SMT202100728T1 (it) 2022-01-10
SI3110438T1 (sl) 2019-05-31
MX2016010954A (es) 2016-11-11
JP6585085B2 (ja) 2019-10-02
KR102515835B1 (ko) 2023-03-31
SMT201900166T1 (it) 2019-05-10
PL3110438T3 (pl) 2019-06-28
EP3110438A1 (en) 2017-01-04
US20170008932A1 (en) 2017-01-12
BR112016019525B1 (pt) 2024-01-02
KR20160124774A (ko) 2016-10-28
JP2017507181A (ja) 2017-03-16
HUE042054T2 (hu) 2019-06-28
CY1121535T1 (el) 2020-05-29
DK3498292T3 (da) 2022-01-03
SG11201606272PA (en) 2016-09-29
ES2899300T3 (es) 2022-03-10
PT3498292T (pt) 2021-11-18
AU2015220369B2 (en) 2018-02-01
CA2939862A1 (en) 2015-08-27
ME03335B (me) 2019-10-20
IL246994B (en) 2020-11-30
MX376079B (es) 2025-03-07
HRP20190412T1 (hr) 2019-04-19
PT3110438T (pt) 2019-03-29
ES2715674T3 (es) 2019-06-05
EP3498292A1 (en) 2019-06-19
SI3498292T1 (sl) 2022-01-31
EP3110438B1 (en) 2019-01-02
WO2015125118A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
HUS2400043I1 (hu) VIII-as faktor kimérafehérjék és alkalmazásuk
IL246994A0 (en) Protein constructs of uspa2 and their uses
IL287825A (en) Structures of sirp-alpha variant and their uses
GB201415344D0 (en) Protein
HUE050893T2 (hu) Protein
PL3099793T3 (pl) Białko
IL251289A0 (en) New peptide derivatives and their use